Voglio sapere a riguardo di…

Federal Register / Vol. 86, No. 233 / Wednesday, December 8, 2021 / Notices Request for Comments In accordance with the Paperwork Reduction Act, 44 U.S.C. 35013520, comments on AHRQs information collection are requested with regard to any of the following: a Whether the proposed collection of information is necessary for the proper performance of AHRQs health care research and health care information dissemination functions, including whether the information will have practical utility;
b the accuracy of AHRQs estimate of burden including hours and costs of the proposed collections of information; c ways to enhance the quality, utility and clarity of the information to be collected; and d ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.
Comments submitted in response to this notice will be summarized and included in the Agencys subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record.
Dated: December 2, 2021.
Marquita Cullom, Associate Director.
FR Doc. 202126561 Filed 12721; 8:45 am BILLING CODE 416090P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and Quality Notice of Meetings Agency for Healthcare Research and Quality AHRQ, HHS.
ACTION: Notice of five AHRQ
Subcommittee meetings.
AGENCY:

The subcommittees listed below are part of AHRQs Health Services Research Initial Review Group Committee. Grant applications are to be reviewed and discussed at these meetings. Each subcommittee meeting will be closed to the public.
DATES: See below for dates of meetings:
1. Healthcare Safety and Quality Improvement Research HSQR
Date: February 23, 2022
2. Healthcare Effectiveness and Outcomes Research HEOR
Date: February 910, 2022
3. Health System and Value Research HSVR
Date: February 1011, 2022
4. Healthcare Research Training HCRT

jspears on DSK121TN23PROD with NOTICES1

SUMMARY:

VerDate Sep<11>2014

16:53 Dec 07, 2021

Jkt 256001

Date: February 242528, 2022
5. Healthcare Information Technology Research HITR
Date: February 2425, 2022
ADDRESSES: Agency for Healthcare Research and Quality Virtual Review, 5600 Fishers Lane, Rockville, Maryland 20857.
FOR FURTHER INFORMATION CONTACT: to obtain a roster of members, agenda or minutes of the non-confidential portions of the meetings. Jenny Griffith, Committee Management Officer, Office of Extramural Research Education and Priority Populations, Agency for Healthcare Research and Quality AHRQ, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone 301 427
1557.
SUPPLEMENTARY INFORMATION: In accordance with section 10 a2 of the Federal Advisory Committee Act 5
U.S.C. App. 2, AHRQ announces meetings of the above-listed scientific peer review groups, which are subcommittees of AHRQs Health Services Research Initial Review Group Committee. The subcommittee meetings will be closed to the public in accordance with the provisions set forth in 5 U.S.C. App. 2 section 10d, 5
U.S.C. 552bc4, and 5 U.S.C.
552bc6. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Agenda items for these meetings are subject to change as priorities dictate.
Marquita Cullom, Associate Director.

69651

Operating Officer, CDC, pursuant to Public Law 92463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel SEP
RFACE22004, Research Grants to Prevent Firearm-Related Violence and Injuries.
Dates: April 48, 2022.
Times: 8:30 a.m.5:00 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact:
Mikel Walters, Ph.D., Scientific Review Officer, National Center for Injury Prevention and Control, CDC, 4770
Buford Highway NE, Mailstop F63, Atlanta, Georgia 303413717, Telephone: 404 6390913; Email:
MWalters@cdc.gov.
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.
FR Doc. 202126576 Filed 12721; 8:45 am
FR Doc. 202126545 Filed 12721; 8:45 am
BILLING CODE 416318P

BILLING CODE 416090P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief
PO 00000

Frm 00041

Fmt 4703

Sfmt 4703

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to
E:FRFM08DEN1.SGM

08DEN1